Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
01:42pm, Thursday, 18'th Feb 2021
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Therapeutics Secures $150M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck Cancer
09:25am, Wednesday, 17'th Feb 2021
Nektar Therapeutics (NASDAQ: NKTR) announces a financing and co-development collaboration with privately-held SFJ Pharmaceuticals to develop Bempegaldesleukin (BEMPEG) CD122-preferential IL-2–pa
Even A Novice Can Spot Nektar Therapeutics' Potential
09:45am, Tuesday, 16'th Feb 2021
NKTR's stock drop over the last few years has been exacerbated by short sellers and bad luck.
Top Stocks To Short Today As Markets Recoup Last Week's Losses
12:56pm, Tuesday, 02'nd Feb 2021
Nearly all of last week's losses have been recovered, and investors seem to be back to focusing on earnings from tech giants, stimulus progress, and the vaccine. With all of this news, Q.ai's deep lea
NKTR Stock Price Increases Over 11% Pre-Market: Why It Happened
08:25am, Monday, 01'st Feb 2021
The stock price of Nektar Therapeutics (NASDAQ: NKTR) has increased by over 11% pre-market today. This is why it happened.
Gamestopping Biopharma: These Three Stocks May See A Short Squeeze Soon
06:47am, Sunday, 31'st Jan 2021
The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.
3 Stocks Wall Street Thinks Will Soar 50% or More in 2021
06:08am, Sunday, 24'th Jan 2021
These stocks have one obvious thing in common.
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
05:00pm, Wednesday, 06'th Jan 2021
SAN FRANCISCO, Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Vir
35% Upside Likely For Nektar Therapeutics?
08:00am, Wednesday, 06'th Jan 2021
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buy
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
04:47pm, Tuesday, 05'th Jan 2021
These are the stocks posting the largest moves after hours on Tuesday.
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
04:20pm, Tuesday, 05'th Jan 2021
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective im
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
12:02pm, Tuesday, 22'nd Dec 2020
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Nektar Therapeutics: A Look At The SITC BEMPEG Data
01:23am, Friday, 20'th Nov 2020
Nectar, a global leader in polymer chemistry-based drug discovery, has no major near-term catalysts, a vast pipeline and numerous big pharma collaborations. It recently published a set of 3 trial data
SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational agents a
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript
11:57pm, Thursday, 05'th Nov 2020
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript
